Tuesday, 2nd December Clinical Oncology Society of Australia 2014 Annual Scientific Meeting

Speakers include F Boyle, J Shaw, K Andrews.

This breakfast session will allow participants to review the latest evidence about effectiveness of scalp cooling for prevention of chemotherapy induced alopecia. Participants discuss strategies for implementation into clinical practice in Australia and share experience of how they have overcome barriers and enhanced patient care.  

This breakfast session is free for conference delegates, but it’s important to register because COSA and Paxman/Regional Health will be providing breakfast! You can register by selecting this breakfast session in the 'add-ons' section of the registration portal. 

There is increasing high level interest in wellness and integrative medicine/oncology in Australia. This session will focus on wellness models in the acute cancer setting and the integration of wellness models into mainstream cancer care: barriers and enablers.

Contributors to the session are: Ian Olver, Chair; David Joske, SolarisCare, Perth WA; Suzanne Grant, Chris O’Brien Lifehouse, Sydney NSW; and Tammy Boatman, Olivia Newton-John Cancer & Wellness Centre, Melbourne VIC.

Topics to be covered include:
· Setting (public/private, integrated or not integrated)
· Rationale for establishment of program
· Business model (including governance & funding mechanisms)
· Services offered
· Service delivery models including paid staff/volunteers or both
· Credentialing, liability, insurance issues
· Evaluation/research
· Consumer engagement

This breakfast session is free for conference delegates, but it’s important to register because COSA will be providing breakfast! You can register by selecting this breakfast session in the 'add-ons' section of the registration portal. 

Welcome by COSA President, A/Professor Sandro Porceddu

Welcome to Country 

Official opening by Professor Helen Zorbas AO, Chief Executive Officer, Cancer Australia

• The changing nature of Stage 4 cancer - Bruce Mann
• The utility and limitations of imaging oligometastatic disease - Michael Hofman
• Tailoring systemic treatments for metastatic disease - Ben Solomon
• Role of Radiotherapy for Oligometastases - Normand Laperriere
• Treatment of metastatic lung cancer: The ESMO Clinical Benefit Scale (ESMO CBS) - Nathan I. Cherny

Presenters to stand next to posters

• Role of Radiotherapy for Brain Metastases - Normand Laperriere
• Liver mets - Benjamin Thomson
• Pulmonary metastatectomy is now an established modality for the newly defined entity of oligometastatic disease - Phillip Antippa
• Pulmonary oligometastatic sarcoma - David Thomas

• Complementary therapies in cancer symptom management - Donald Abrams
• Long term complications of cancer therapy – Neuropathy - John Coutsouvelis
• Long term complications of cancer therapy Cardiology - Daniel McKavanagh

• Imaging surveillance in the molecular era: breast and renal carcinoma - Kate Moodie
• Screening for colorectal cancer – current recommendations and assessment of efficacy! - Alex Boussioutas
• Risk reduction strategies in familial breast and ovarian cancer - Melanie Wuttke
• Active surveillance for low risk prostate cancer : an Australian experience - Mark Frydenberg

Chair: Chris Scott

• Exercise prescription for bone metastatic cancer: feasible and effective - Rob Newton
• Inactivity and functional decline in lung cancer - Catherine L Granger
• Mindfulness as a strategy for living well during and after cancer - Jeremy Couper
• Health literacy in relation to cancer: Addressing the silence about and absence of cancer discussion among Aboriginal people, communities and health services - Carla Treloar

• Immunohistochemical assessment of epithelial mesenchymal transition with tumour satellite distance as a prognosticator in oral squamous cell carcinomas - Karen Boaz
• Synergistic Antitumor Efficacy of A Modified Survivin Peptide Vaccine and Temozolomide in A Murine Model of Cerebral Glioma - Zhengwen He
• Tumorspheres derived from clonally expanding peripherally circulating tumor cells exhibit stem cell features and self-renewal properties. - Katharina Pachmann
• Aberrant Novel Expression of (Ser240Thr) is Associated with Pathological Findings and p53 Alteration in Oral Squamous Cell Carcinoma - Saima Saleem

• Patterns of palliative and psychosocial care in metastatic non-small cell lung cancer in South Western Sydney - Kirsten Duggan
• Is multidisciplinary team review associated with survival in lung cancer patients? - Tracey Guan
• Equity of access to non-small cell lung cancer surgery in Queensland: A population-based study - Nathan Dunn
• Identifying the needs of Aboriginal and Torres Strait Islander peoples affected by lung cancer. - Barbara Page
• Building an implementation science program in lung cancer care: results from Sydney Catalyst Translational Cancer Research Centre. - Nicole Rankin
• The influence of patients’ experience of symptoms on delay in diagnosis of lung cancer: findings from the Victorian Component of International Cancer Benchmarking Project (ICBP) Module 4 - Victoria White

• Cancer survivorship: The future is now - Mary McCabe
• New roles for GPs in cancer survivorship - David Weller
• Physical activity and cancer survivorship: From symptom control to survival - Kerry Courneya
• Outcome measures in survivorship - Irene Higginson

• Melanoma shared care. A tripartite approach for survival, the patient, their GP and their specialist - Colleen P. Berryman
• The Development of an e-learning package for multidisciplinary clinicians on cancer malnutrition - Amber Kelaart
• Can media coverage influence research article citations? - Yaping Liu
• Do patients with advanced cancer want to discuss and pay for unfunded expensive anticancer drugs? - Linda Mileshkin
• Evaluation of the first year of the Sydney Survivorship clinic at Concord Cancer Centre: Feasibility, function and clinical pathways - Janette Vardy

• Targeting the RON/MST1R receptor using LCRF004, may provide an effective novel interventional strategy in malignant pleural mesothelioma - Anne-Marie Baird
• Targeting the Hedgehog signalling pathway in triple negative breast cancer - Mun Hui
• Effects of taxol in combination with cyclooxygenase inhibitors on expression of cyclin D1 and angiogenesis in human ovarian cancer xenografts - Wei Li
• Symptom clusters in cancer patients: myth or reality? The impact of multiple symptoms on overall quality of life, physical health and psychological distress during cancer treatment - Carlo Pirri
• Outcomes from a pilot randomised controlled trial of early and intensive dietary counselling in lung cancer patients receiving (chemo)radiotherapy. - Nicole Kiss

Presenters to stand next to posters

• The use of  label-free LC-MS/MS approach to identify signaling pathways associated with prostate cancer radioresistance - Lei Chang
• Anticancer drug transport to breast cancer cells using mineral nanoparticles - Chia Yuen Chong
• Selective cytotoxicity of gemcitabine on superficial malignant vs. normal human urothelial cells and the effects of hyperthermia - Stefanie Farr
• Gemcitabine enhances release of ATP but not acetylcholine or PGE₂ from bladder urothelial cells - Stefanie Farr
• Relative cytotoxic potency and cell death mechanisms of α1-adrenoceptor antagonists on prostate cancer cell lines - Amanda Forbes
• Pre-treatment information needs and preferences of radiotherapy patients - Claire Goodwin
• Alterations in bladder urothelial acetylcholine, ATP, prostaglandin E2 and inflammatory cytokines by the chemotherapeutic agent epirubicin - Sung Hyun Kang
• Intravesical mitomycin C treatment alters urothelial function and detrusor contraction - Sung Hyun Kang
• Energy and protein intake in oncology patients at risk of skeletal muscle atrophy - Sarah King
• Effects of combining Taxol and SC-560 on angiogenesis of ovarian cancer in vivo - Wei Li
• The effect of caffeine on ABCB1 efflux transporter function - Chin-Min Lin
• Modulation of P-glycoprotein function by curcumin-loaded nanoparticles - Nai-Yu Liu
• The new selective GLP-2 receptor agonist, Elsiglutide, improves irinotecan-induced diarrhoea and mucositis in the rat. - Bronwen Mayo
• Apoptosis, proliferation and inflammation are improved after treatment with the new selective GLP-2 receptor agonist, Elsiglutide, in a rat model of irinotecan-induced mucositis. - Bronwen Mayo
• Cyclophosphamide and ifosfamide enhancement of bladder sensory nerve activity - Kylie Mills
• Diagnosis and molecular targeting for individualized treatment of patients with pre-neoplastic lesions and locally advanced cervical cancer - Pablo Moreno Acosta
• No More Vague Descriptors: Building competency in assessment, in collaboration with all stakeholders. The development of a comprehensive assessment tool for patients in the Day Oncology setting at Cabrini Malvern - Briege O'Donnell
• Somatic mutations of the EGFR, KRAS and BRAF genes: homogeneity in single cells from cell lines and heterogeneity in circulating epithalial tumor cells (CETC) as determined using the Cobas® z 480 analyzer - Katharina Pachmann
• A complex Qstream© pain assessment intervention on cancer nurses’ pain screening and assessment practices: results from a quasi-experimental study. - Jane L Phillips
• Upregulation of RORα inhibit proliferation, invasion and migration of human gastric cancer cells induced by diallyl disulfide - Su Qi
• Why early treatment of obesity matters:  pAkt/mTor and glycolysis is activated in obese women during the initiation of triple-negative breast cancers and can be targeted by metformin chemoprevention - Victoria Seewaldt
• β-carotene, a carotenoid, is a potential inhibitor of multidrug resistant protein - Yu-Ning Teng
• Integrated Target Discovery in the EMPathy Breast Cancer Network - Multidimensional Analysis of Epithelial Mesenchymal Plasticity (EMP) in Experimental Systems. - Erik (Rik) W Thompson
• Preventive screening for cancer among people attending an Aboriginal Community Controlled Health Service - Heidi Turon
• Effects of high dose thoracic radiotherapy with concomitant and sequential trastuzumab on isolated rat aorta: A functional study - Oguzhan Yildiz
• c-myc Plays Part in Drug Resistance Mediated by Bone Marrow Stromal Cells in Acute Myeloid Leukemia - yizhuo zhang
• Combined Inhibition Of BTK And PI3Kδ As A Potential Therapeutic Strategy In Mantle Cell Lymphoma - yizhuo zhang
• Improving patient experience in a day oncology service - Emma F. Alder
• The significance of data in capturing a bird’s eye view of a Hospital and Health Service's (HHS) progress - Eliza Bott
• Using an action research approach to quality improvement of chemotherapy day unit documentation: Engaging health professionals and implementing sustainable change - Lisa Brady
• Filling the gaps: Implementation and evaluation of the Haematology/Oncology Plan of Care Documentation in a Chemotherapy Day Unit   - Lisa Brady
• Chemotherapy services, safety hierarchy – What you need to know - Maree Bransdon
• Outreach care in a changing health landscape – Making the link - Maree Bransdon
• The ‘specter’ of cancer: Secondary trauma for health professionals providing cancer support and counseling - Lauren J. Breen
• Reducing health costs by treating low-risk neutropenic fever patients at home - Christine Brown
• Achieving consensus in the management of neutropenic fever and sepsis in cancer - Christine Brown
• Involving family in treatment decision-making: A new conceptual framework and consultation strategies - Phyllis Butow
• Cancer Council Helpline 13 11 20: Who uses this information and support service – and why not? - Monica Byrnes
• Malnutrition prevalence in an outpatient cancer care setting - Belinda Camilleri
• The evaluation of clinical pharmacy services in an ambulatory cancer day care unit - Christine V. Carrington
• Time from diagnosis of rectal adenocarcinoma to commencement of long course chemoradiotherapy (LCCRT) for metropolitan versus rural patients referred to a Queensland tertiary referral hospital - Hayden Christie
• A 15 year longitudinal study of breast cancer treatment outcomes in a region - Paul Craft
• Radiotherapy for people with cancer: What do written information materials tell them? - Haryana M. Dhillon
• Implementation of a comprehensive geriatric assessment program at the Royal Perth Hospital (RPH) for newly diagnosed older cancer patients - Andrew Kiberu
• Fast track colonoscopy for positive faecal occult blood testing (+FOBT) in a public hospital setting - Donna Gillies
• You can lead a horse to water, but you can’t make it drink: Does a needs assessment tool increase discussion of psychosocial concerns of people with advanced cancer?  - Afaf Girgis
• Documentation of antimicrobial therapy in haematology and oncology - A nursing led Antimicrobial Stewardship intervention pilot project - Yvette Gomez
• Lung cancer MDT activity in Queensland: are we making any progress? - Tracey Guan
• Partnering with patients: a symptom management diary and passport – Created by our patients and clinical partners with clear purpose - Bridget Gurry
• Unplanned allied health admissions to hospital for people newly diagnosed with cancer - Livia Haddow
• Queensland Cancer Quality Index: tracking Queensland’s progress in improving cancer care - Hazel Harden
• Results of an electronic oncology pharmacy observational quality assurance audit tool - Russell Hill
• Successful management of etoposide hypersensitivity in patients with gynaecological malignancies - Huda Ismail
• How much do cancer care clinicians know about cancer malnutrition? - Amber Kelaart
• Patients with lower health literacy in radiation oncology: A nursing perspective - Aaron Kok
• Examining determinants of “access” to radiotherapy – Does the introduction of a local publicly funded radiotherapy service to regional NSW impact on the uptake of breast conserving treatment for early breast cancer here?  - Johnson Lam
• Patient-reported experience of care by prostate cancer specialist nursing service - Wei-Hong Liu
• Why are a large proportion of prostate cancer cases recorded as having “unknown” stage of disease in an Australian population-based registry? A study of possible health service factors - Qingwei Luo
• Melanoma in a rural Australia, a retrospective 10 year audit of diagnosis and management in the Wimmera. - James A McCracken
• Cetuximab use in metastatic colorectal cancer at five large Queensland public hospitals: comparison to key clinical trials - Daniel McKavanagh
• Examining the general practitioner perspective on utilising family history  to screen for colorectal cancer. - Sundresan Naicker
• Music’s relevance for people affected by cancer across the span: Implications for cancer care - Clare O'Callaghan
• Allied health integrated regional pathway for head and neck cancer patients - Juanine Passfield
• Optimal Care Pathways: Achievements and future directions - Alexandra Philpott
• Research Governance for regional clinical trials. - Sandra Robinson
• The establishment of chemo@home: An integrated model of patient-centred service delivery for chemotherapy patients - Lorna Rogers
• Evaluating an evidence-based care pathway for the management of anxiety and depression in cancer care: A Delphi Consensus Study. - Joanne Shaw
• Defining and prioritising success factors for coordinated cancer care - Tim Shaw
• Barriers to radiotherapy utilization: Consumer perceptions of issues that may influence radiotherapy related decisions - Puma Sundaresan
• Health Professionals perceptions of the impact of access and treatment related practicalities on referrals for radiotherapy and its uptake by consumers   - Puma Sundaresan
• Health service access for Aboriginal people associated with level of Aboriginal community engagement  - Dianne O'Connell
• Oncology patients overwhelmingly support tissue banking - Heidi Turon
• How good is the quality of evidence for grief counselling? A systematic review - Heidi Turon
• Empowering youth engagement through the Victorian and Tasmanian Youth Cancer Advisory Board (YCAB) - Samantha A Van Staalduinen
• A process-based IT system to manage multidisciplinary meetings in a more flexible way - Stephen Vaughan
• Rural oncology care via teleoncology and outreach clinics: patient and staff perspectives and comparisons. - Holly Wyeth
• Nivolumab and ipilimumab in first-line non-small-cell lung carcinoma (NSCLC): interim phase I results - Scott J Antonia
• DHMEQ may provide a therpeutic option in targeting inflammatory mediated acquired and intrinsic cisplatin resistance in non-small cell lung cancer - Anne-Marie Baird
• Sustained exposure to TNF-α and IL-1β increases the invasion, adhesion and proliferative potential of a normal bronchial epithelial cell line  - Anne-Marie Baird
• Epidermal Growth Factor Receptor (EGFR) co-mutated advanced non-small cell lung cancer (NSCLC) and response to EGFR tyrosine kinase inhibitors (TKIs) - Megan B. Barnet
• The frequency of allied health interventions to lung cancer patients at Sunshine Hospital Radiotherapy Centre: Data to guide future service delivery - Hollie Bevans
• Nivolumab in patients with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis. - Julie R Brahmer
• Predictors of postoperative mortality after lung cancer surgery - Nathan Dunn
• Patterns of MDT review vary by HHS of residence for NSCLC patients in Queensland - Tracey Guan
• Systemic treatments in advanced non-small cell lung cancer (NSCLC): a systematic review  - James P Harrison
• Prognosis of dynamic MR imaging and diffusion weighted imaging for stage III non-small cell lung cancer patients treated with concurrent chemo-radiotherapy  - Baosheng Li
• Circulating tumor cells in peripheral and pulmonary venous blood predict poor long-term survival in surgically resected non-small cell lung cancer patients - Zhidong Liu
• The feasibility of a pragmatic distance-based intervention to increase physical activity in lung cancer survivors - Carolyn McIntyre
• Survival times of patients with metastatic non-small cell lung cancer (NSCLC) starting first-line chemotherapy in routine clinical practice versus contemporary randomised trials - Jane L Parry
• EBUS replaces other invasive diagnostic investigations and does not impact on time to management decision for lung cancer - Neli Slavova-Azmanova
• Under hypoxic tumor microenvironment, DT-13 inhibited human lung adenocarcinoma growth and metastasis via changing the distribution and down-regulation expression of NMⅡA - xiaowen yu
• Head and neck cancer (HNC) patients beyond 2 years of disease control: Preliminary analysis of ILEA (Intensity modulated radiotherapy late effect assessment) scale. - Trinanjan Basu
• Shifts in perceptions of self associated with the experience of ovarian cancer - Rebecca Carlson
• Family functioning during oncology treatment: International perspectives - Elisabeth Coyne
• Development of an evidence based symptom checklist for detecting symptoms of recurrence in women with endometrial cancer - Audra de Witt
• Prevalence and associates of the top high/very high unmet needs of Australian haematological cancer survivors - Alix Hall
• A comparison of the unmet needs of younger and older adult haematological cancer survivors - Alix Hall
• Emotion-regulating coping processes in men with cancer - Michael A Hoyt
• Development and evaluation of an online education model on cancer survivorship & supportive nursing care - Michael Jefford
• Living with multiple myeloma: a focus group study of concerns and unmet needs - Leanne Monterosso
• Understanding lymphoma and leukemia survivors’ concerns: a focus group study - Leanne Monterosso
• Qualitative results of the exercise programming preferences and activity levels among adolescents and young adults who have had an experience of cancer. - Andrew Murnane
• Clinical assessment of cancer-related fatigue: current practice vs. clinical guidelines - Elizabeth JM Pearson
• Bone health management of breast and prostate cancer survivors receiving hormonal therapy - Rachel Roberts
• Which strategies have been demonstrated to be effective in managing bone loss in breast and prostate cancer survivors post hormone therapy, and how well are they employed in clinical practice? - Rachel Roberts
• Nutritional status as a determinant of survival in women with gynecological tumors - Camila S. Rodrigues
• Integrative Literature Review of Instruments used to assess Informational and Practical Needs of Acute Leukaemia and Lymphoma Survivors. - Karen M Taylor
• Using web-enabled technology to support men with prostate cancer - Addie Wootten
• Towards a paradigm shift: psycho-social stress in cancer patients living in rural regions, following active therapy, with care not augmented by a formal Survivorship Care Program - Mari P Lashbrook
• The Psychological Impact of a Pilot Whole-Body Screening Trial (SMOC) on individuals with Li –Fraumeni Syndrome - Kate A McBride
• PARAGON- Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms: ANZGOG 0903 - Linda Mileshkin
• The Inherited Cancer Connect (ICCon) mutation-carrier database - Lara Petelin
• Comparing the Impact of Melatonin and Captopril on Early Effects of Radiation on the Heart Tissue by Studying GSH, MDA and LDH Enzyme Activity in Rats - Farnaz Tabatabaie

• Integrative cancer care: Who, what, why, when and how - Donald Abrams
• Focusing on coping with a diagnosis of gynaecological cancer - and improving outcomes for women - Lynette Joubert
• Patient Rated Outcomes in an RCT of immediate versus delayed exercise programs in patients with haematological malignancies; and to assess use of complementary therapies at SolarisCare centres in Western Australia - David Joske
• Acupuncture for cancer patients - Xiaoshu Zhu

• Childhood cancer survivors: What are their motivators and barriers to participating in long term follow-up care? - Richard Cohn
• The ‘new normal’: late effects of a cancer diagnosis in adolescence and young adulthood - Kylie Lewis
• Post Testicular Cancer Treatment Cognition – Clearing the Fog - Ian Olver
• Back to the beginning: what advice to give women regarding lymphoedema - Sharon Kilbreath
• An Imaging-Based Algorithm for the Management of Lymphoedema in the Australian setting - Ramin Shayan

• Novel approaches to NSCLC 2015:  COSA 2014 annual meeting - Thomas Lynch
• G-CSF promotes metastasis in preclinical models of breast cancer - Robin L. Anderson
• Circulating tumour cells and radiotherapy - Michael MacManus
• They say the odds are good, but I can’t stop thinking about it: Responding to Fear of Cancer Recurrence - Jane Turner
• Facilitating the transition to palliative care - Jennifer Philip

Speakers followed by panel discussion

• Cancer and inflammation - Stephen Clarke
• The GPS and the NLR: links between the tumour and systemic inflammation - Donald C. McMillan
• Inflammation and cognition - Janette Vardy
• Mechanisms and markers of inflammation: microRNA, genomics, proteomics - Connie Diakos
• Therapeutic interventions for systemic inflammation to improve anti-tumour efficacy - Kellie Charles

• Survival of women diagnosed with breast cancer in the Australian Breast Cancer Family Study - John L Hopper
• Efficacy of home based exercise for reducing cancer related fatigue in breast cancer patients undergoing radical radiotherapy: A randomised controlled trial - Prue Cormie
• Are we ready to provide rehabilitation and health promotion interventions to cancer survivors? - Paula Howell
• Cancer Survivorship 101: findings from the Victorian pilot projects of post-treatment survivorship care - Nicole Kinnane
• Standardizing patient-centered outcomes measurement for localized prostate cancer: An international, cross-disciplinary effort. - Kim L Moretti
• Positive Change for Life – Preliminary results of a 12 month lifestyle intervention program on metabolic syndrome risk factors in haemopoeitic stem cell transplant survivors - Elizabeth Viner Smith

• Qualitative analysis of interviews with men with prostate cancer: understanding the impact of a prostate cancer specialist nursing intervention on the post-treatment experience.  - Lynda J Carnew
• Hospital-based care in the last year of life for people dying from cancer in New South Wales: a retrospective cohort study - David Goldsbury
• Patients perceptions of what may have caused their cancer: A cross-sectional investigation of Vietnamese radiotherapy cancer patients - Alix Hall
• What drives the cost of cancer treatment? Insights from an analysis of a longitudinal cohort (Cancer 2015) linked to administrative reimbursement data - Paula Lorgelly
• Cancer patients’ preferences for involvement in research and consumer activities: A cross-sectional survey - Lisa J Mackenzie

Immune checkpoints are a collection of molecular networks that regulate the immune system. Therapeutic approaches that inhibit the checkpoint molecules have demonstrated considerable benefit for cancer therapy. The use of these immuno-oncology drugs represent a new era in clinical management of patients with cancer and differ considerably from surgery, chemotherapy, radiotherapy and targeted therapy-based treatment methods for cancer. This symposium will provide an update on the latest developments in immuno-oncology as well as discuss best practices for managing patients receiving treatment with immuno-oncology drugs. Attendees will have the opportunity to share their experiences, participate in the discussion and ask questions to our experts. Join us at COSA 2014 to learn about the latest developments and considerations on the safety and efficacy of immune-oncology therapies.

This dinner symposium is free for conference delegates, but it’s important to register because Bristol-Myers Squibb will be providing dinner! You can register by selecting this dinner symposium in the 'add-ons' section of the registration portal.